Boceprevir: A novel NS3/4 protease inhibitor for the treatment of hepatitis C
Klibanov OM, Vickery SB, Olin JL et al. Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C. Pharmacotherapy. 2012; 32:173-90.
A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system
Koh Y, Yap CW, Li SC. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system. Int J Med Inform. 2008; 77:421-30.
Talbert RL, DiPiro JT, Matzke GR et al., eds. 8th ed New York: McGraw-Hill
Matzke GR. Disorders of sodium and water homeostasis. In: Talbert RL, DiPiro JT, Matzke GR et al., eds. Pharmacotherapy: a pathophysiologic approach. 8th ed. New York: McGraw-Hill; 2011:745-64.
Lawry GV, McKean SC, Matloff J et al., eds. New York: McGraw-Hill
Schaffer AC. Urinalysis and urine electrolytes. In: Lawry GV, McKean SC, Matloff J et al., eds. Principles and practice of hospital medicine. New York: McGraw-Hill; 2012:772-82.
Food and Drug Administration. Victrelis (boceprevir) medical review. www.accessdata.fda.gov/drugsatfda-docs/nda/2011/202258Orig1s000MedR.pdf (accessed 2013 Jun 12).
Association of prenatal and postnatal exposure to lopinavirritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers
Warszawksi SJ, Kariyawasam D, Le Chenadec J et al. Association of prenatal and postnatal exposure to lopinavirritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA. 2011; 306:70-8.
Interferon-alpha is a predisposing risk factor for carbamazepine-induced hyponatremia: A case of syndrome of inappropriate antidiuresis caused by interferon-alpha therapy
Tanaka M, Kamoi K, Takahashi T. Interferon-alpha is a predisposing risk factor for carbamazepine-induced hyponatremia: a case of syndrome of inappropriate antidiuresis caused by interferon-alpha therapy. Int J Gen Med. 2008; 1:21-5.
Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma
Soetekouw PM, Koopman M, Burger D et al. Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma. Acta Oncol. 2009; 48:154-6.
Conversion from latent to symptomatic Sheehan's syndrome by pegylated interferon therapy for chronic hepatitis C
Kanda K, Kayahara T, Seno H et al. Conversion from latent to symptomatic Sheehan's syndrome by pegylated interferon therapy for chronic hepatitis C. Intern Med. 2008; 47:939-41.
Severe hyponatremia due to syndrome of inappropriate secretion of antidiuretic hormone in a patient receiving interferonalpha for chronic myeloid leukemia
Lei KI, Wickham NW, Johnson PJ. Severe hyponatremia due to syndrome of inappropriate secretion of antidiuretic hormone in a patient receiving interferonalpha for chronic myeloid leukemia. Am J Hematol. 1995; 49:100.
A phase II trial of doxorubicin and interferon alpha 2b in advanced, nonmedullary thyroid cancer
Argiris A, Agarwala SS, Karamouzis MV et al. A phase II trial of doxorubicin and interferon alpha 2b in advanced, nonmedullary thyroid cancer. Invest New Drugs. 2008; 26:183-8.
A case of Addison's disease which became worse during interferon therapy: Insulin secretion under hypoosmolarity
Oshimoto K, Shimizu H, Sato N et al. A case of Addison's disease which became worse during interferon therapy: insulin secretion under hypoosmolarity. Nihon Naibunpi Gakkae Zasshi. 1994; 70:511-6.
Glucocorticoid resistance and the immune function in the immunodeficiency syndrome
Norbiato G, Bevilacqua M, Vago T et al. Glucocorticoid resistance and the immune function in the immunodeficiency syndrome. Ann N Y Acad Sci. 1998; 840:835-47.
